TENT S	TRANSMITTAL FORM (to be used for all correspondence after initial fi	Approved for use through 04/30/2003 MB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/734,949 Filing Date December 13, 2003 First Named Inventor Rodriguez-Sarmiento Art Unit Examiner Name Attorney Docket Number 21247 US ENCLOSURES (Check all that apply)							
	Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks After Allowance Communication to Group (Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Remarks References B1 to B3 and C1 to C9.							
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
	L baroby cartify that this correspondence is being to	ERTIFICATE OF TRANSMISSION/MAILING ansmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class or Patents, P.O. Box 1450, Alexandria, VA 22313 on this date March 15, 2004							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Serial No. 10/734,949 Filed: December 13, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

139361

SEMENTE OF FORM 1449A/PTO INFORMATION BISCLOSURE STATEMENT BY APPLICANT MAR 1 7 2004 (Use several sheets innecessary)					Complete if Known				
					Application Number	10/734,9	949		
					Filing Date		er 13, 2003		
					First Name Inventor Rodrigu		ez-Sarmiento		
Sheet	10	of of	inceessury)		Attorney Docket Number	21247 U	JS		
	Lin	(TO NO.		U.S. PA	TENT DOCUMENTS				
	U.S. Patent Document			ument	ST CD		Data of Dublication of		
Examiner Initials'	Cite No.			Kind Code	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document		
Illitials	140.			(if known)			MM-DD-YYYY		
	A								
-									
			<u> </u>						
					PATENT DOCUMENTS			-	
	<u></u>	Foreign Patent Document		ment	N CD-44		Date of Publication of	T ⁶	
Examiner Initials'	Cite No.¹	Office ³	Number 1	Kind	Name of Patentee or Applicant of Cited Document		Cited Document		
Initials				Code ⁵ (if known)		MM-DD-YYYY			
	B1	WO 01	O 01/34172		Vela Pharmaceuticals Inc.		05/17/2001		
	B2	WO 97/33572			Somerset Pharmaceuticals Inc.		09/18/1997	L.	
	B3	WO 96/40095		_	Harris, R. Y.		12/19/ 1996		
						· · · ·			
Examiner	Cite	Include no			LITERATURE DOCUMES ITAL LETTERS), title of the article		oriate) title of the	T ²	
Initials'	No.1	item (book, magazine, journal, serial			l, symposium catalog, etc.), date, page(s), volume-issue number(s),				
	-	publisher, city and/or country where published Deals of all Drag North Acad Sci Vol 95: pgg 4024 4029 (1099)							
	C1	Bach et al., Proc. Natl. Acad. Sci. Vol. 85: pgs. 4934-4938 (1988)							
	C2	Cesura & Pletscher, Prog. Drug Research Vol. 38: pgs. 171-297							
		(1992)							
	C3	Fowler et al., J. Neural. Transm. Vol. 49: pgs. 1-20 (1980)							
	C4	Benedetti et al., Biochem. Pharmacol. Vol. 38: pgs. 555-561 (1989)							
	C5	Saura et al., Neuroscience Vol. 70: pgs. 755-774 (1996)							
	C6	Bentué-Ferrer et al., CNS Drugs Vol. 6: pgs. 217-236 (1996)							
	C7	Gardner et al. J. Clin. Psychiatry Vol. 57: pgs. 99-104 (1996)							
	C8	Schlaeger & Christensen, Cytotechnology Vol. 30: pgs. 71-83 (1999)							
	C9	Zhou & Panchuk-Voloshina, Analytical Biochemistry Vol. 253: pgs.							
		169-174 (1997)							
Examiner		Date Cor	nsidered						
Signature	1	1					i	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Tenter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.